[3H]2-phenylaminoadenosine ([3H]CV 1808) labels a novel adenosine receptor in rat brain.
Earlier studies have demonstrated that the vasoactive compound CV 1808 displays 10-fold selectivity for the adenosine A2 receptor, and as such, was the first reported A2-selective agonist. After the radiolabeling of CV 1808, its binding characteristics were evaluated in rat striatal, cortical and hippocampal membranes. Using 5 nM [3H]CV 1808, unlabeled CV 1808 produced shallow inhibition curves in all three brain areas, with 61 to 75% of the binding displaying IC50 values of 16 to 24 nM, whereas the remaining 28 to 37% of binding had lower affinity (IC50 595-1130 nM). The A2-selective agonist CGS 21680 and the nonselective adenosine agonist 5'-N-ethylcarboxamidoadenosine displayed very low affinity (IC50 > 10 microM). The A1-selective compound N6-cyclopentyladenosine inhibited only 28 to 44% of specific binding, with IC50 of 272-1750 nM. In contrast, the nonselective adenosine antagonist CGS 15943A inhibited specific binding by 48 to 64% (at 1 microM) with IC50 ranging from 106 to 295 nM. Additionally, several novel adenosine analogs fully inhibited specific binding, producing multicomponent inhibition curves. Electrophysiological studies in porcine coronary artery cells demonstrated that CV 1808, but not CGS 21680, 5'-N-ethylcarboxamidoadenosine and N6-cyclopentyladenosine, activated potassium channels. Further, the CV 1808-induced activation was blocked by CGS 15943A. These results indicate that [3H]CV 1808 binding consists of two components in rat brain: a low-affinity site with A1-like characteristics, and a novel high-affinity site, designated as the A4 receptor, where potassium channel activation appears to be a functional correlate.
Cornfield
L J
LJ
Research Department, CIBA-GEIGY Corporation, Summit, New Jersey.
Hu
S
S
Hurt
S D
SD
Sills
M A
MA
D000241:Adenosine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D000345:Affinity Labels; D000818:Animals; D001665:Binding Sites; D001923:Brain Chemistry; D007700:Kinetics; D008297:Male; D010627:Phenethylamines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects; D011983:Receptors, Purinergic / Q000187:drug effects*; D014316:Tritium
D000345:Affinity Labels; D010627:Phenethylamines; D011942:Receptors, Adrenergic, alpha; D011983:Receptors, Purinergic; D014316:Tritium; C061282:2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; C026708:2-phenylaminoadenosine; D000241:Adenosine